Datopotamab ELISA Kit

Catalog No.

KDC43302

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative competitive enzyme immunoassay technique. Recombinant Human TACSTD2 has been pre-coated onto a microplate. Standards or samples are premixed with biotin-labeled antibody and then pipetted into the wells. Datopotamab in the sample competitively binds to the pre-coated protein with biotin-labeled Datopotamab. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in inversely proportion to the amount of Datopotamab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Datopotamab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

78.13 - 5,000 ng/mL

Sensitivity

82.55 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <20%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <20%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

	Intra-Assay Precision			Inter-Assay Precision
Sample	1	2	3	1	2	3
n	16	16	16	24	24	24
Mean (ng/mL)	2635.7	603.2	131.1	2921.6	550.4	105.1
Standard deviation	432.3	110.6	25.0	427.4	107.7	21.2
CV (%)	16.4	18.3	19.0	14.6	19.6	20.2

 

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.

Alternative Names

DS-1062, DS-1062a, Datopotamab deruxtecan, CAS: 2267989-53-5

An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer., PMID:40515573

Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data., PMID:40507234

Synergistic strategies: ADC-PARP inhibitor combinations in triple-negative breast cancer therapy., PMID:40494034

Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial., PMID:40450142

Efficacy and Safety of Antibody-Drug Conjugates for Lung Cancer Therapy: A Systematic Review of Randomized and Non-Randomized Clinical Trials., PMID:40430899

Cost-effectiveness of datopotamab deruxtecan in previously treated advanced nonsquamous NSCLC., PMID:40388791

Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing., PMID:40367401

Datopotamab Deruxtecan: First Approval., PMID:40323341

Preclinical Activity of Datopotamab Deruxtecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2, in Uterine Serous Carcinoma., PMID:40299780

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer., PMID:40297626

Therapeutic Potential of Datopotamab Deruxtecan in the Treatment of Advanced Non-Small Cell Lung Cancer: Evidence to Date., PMID:40291609

[Diffuse interstitial lung disease induced by antibody-drug conjugates]., PMID:40263022

Targeting Lung Cancer with Precision: The ADC Therapeutic Revolution., PMID:40238068

FDA approves Datroway: a novel therapy for HR-positive, HER2-negative metastatic breast cancer., PMID:40212175

[Standard of care of EGFR mutated metastatic NSCLC in first treatment and beyond progression]., PMID:40155080

Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer., PMID:40153734

Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer., PMID:40153615

Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis/stomatitis., PMID:40139260

Antibody-drug conjugates in breast cancer: current evidence and future directions., PMID:40114224

Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy., PMID:40082588

Antibody-drug conjugates in elderly patients with breast cancer., PMID:40020509

Datopotamab deruxtecan (Datroway) for advanced breast cancer., PMID:40009990

TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer., PMID:39917260

Beyond failure of endocrine-based therapies in HR+/HER2 negative advanced breast cancer: What before chemotherapy? A glimpse into the future., PMID:39900320

Management of nausea and vomiting induced by antibody-drug conjugates., PMID:39878905

OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models., PMID:39786401

Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study., PMID:39761483

Antibodies to watch in 2025., PMID:39711140

Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis., PMID:39709655

Emerging Therapies for Brain Metastases in NSCLC, Breast Cancer, and Melanoma: A Critical Review., PMID:39625633

Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models., PMID:39585341

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions., PMID:39555080

TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer., PMID:39469838

Understanding the chemistry & pharmacology of antibody-drug conjugates in triple-negative breast cancer with special reference to exatecan derivatives., PMID:39460856

Can We Find a Place for Trophoblast Cell Surface Antigen 2-Targeted Antibody-Drug Conjugates in Lung Cancer?, PMID:39353165

Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial., PMID:39277672

Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial., PMID:39277671

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01., PMID:39265124

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study., PMID:39250535

Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma., PMID:38981151

Blockade of SIRPα-CD47 axis by anti-SIRPα antibody enhances anti-tumor activity of DXd antibody-drug conjugates., PMID:38843278

TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy., PMID:38686016

Perspectives on geriatric oncology research presented at the 2023 San Antonio Breast Cancer Symposium: A Young International Society of Geriatric Oncology report., PMID:38677935

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study., PMID:38652877

Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation., PMID:38648979

Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer., PMID:38560142

Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan., PMID:38502995

Best of the year: Advanced breast cancer in 2023., PMID:38401422

Antibodies to watch in 2024., PMID:38178784

Document Download

Datopotamab ELISA Kit.pdf